{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-040919","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.513569+00:00","generated_at":"2026-06-21T23:04:24.148381+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant prices $150M primary/secondary offering at $5.00 per share","bullets":["Company sold 20M shares for ~$100M gross; selling shareholders sold 10M for ~$50M; $5.00/share.","Underwriter granted 30-day option to purchase up to $22.5M additional common shares.","Roivant expects cash position to fund operations into H2 2025; proceeds not received from selling shareholders.","Offering closed on Nov 10, 2022; sole bookrunner Cantor Fitzgerald.","Registration statement effective Oct 3, 2022; prospectus supplement filed Nov 8."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-040919","json":"https://secwatch.observer/filing/0001140361-22-040919.json","markdown":"https://secwatch.observer/filing/0001140361-22-040919.md","text":"https://secwatch.observer/filing/0001140361-22-040919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/0001140361-22-040919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/ny20005775x4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:04:24.148381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71f8321d19f3b4ec2df6ab1a87fdecc699474b82","claim":"Roivant Sciences Ltd. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at $150 million (effective 2022-11-08).","evidence_excerpt":"On November 8, 2022, Roivant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, and the selling shareholders named therein (the “Selling Shareholders”) relating to the issuance and sale in an underwritten offering (the “Offering”) of 30,000,000 (the “Shares”) of the Company’s common shares, par value $0.0000000341740141 per share, at an offering price of $5.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/0001140361-22-040919-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"$150 million"},{"label":"Effective","value":"2022-11-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}